-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Your Chemo is No Good Here: Management of High-Risk MCL

Program: Education Program
Session: A Shifting Landscape: Treatment of MCL
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Education, Treatment Considerations
Monday, December 9, 2024, 10:30 AM-11:45 AM

Kami J. Maddocks, MD

The James Cancer Center, The Ohio State University, Columbus, OH

Disclosures: Maddocks: MorphoSys: Consultancy; BMS: Consultancy; Gilead/KITE: Consultancy; AbbVie: Consultancy; Incyte: Consultancy; Janssen: Consultancy; ADC Therapeutics: Consultancy; AstraZeneca: Consultancy; Lilly: Consultancy; Genentech: Consultancy; Genmab: Consultancy.

OffLabel Disclosure: There is currently not a Food and Drug Administration Approval for any of the targeted therapies in the initial treatment of MCL although there is data which will be discussed and listings in treatment guidelines.

See more of: A Shifting Landscape: Treatment of MCL
See more of: Education Program
Previous Presentation | Next Presentation >>